Imaging Control Study, 3D Echo, MR and RHC. (PARIS)
Prostanoid Therapy in Severe Pulmonary Arterial Hypertension - Imaging Control Study, 3D Echo, MR and RHC.
The aim of the study is to intensify the follow up of patients with pulmonary arterial hypertension via modern imaging guided methods in due consideration of the possibilities of three-dimensional echocardiography in order to optimize their specific therapy.
The hypothesis is that the increased use of modern imaging guided tools is essential for the follow up.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Upper Austria
-
Linz, Upper Austria, Austria, 4020
- Recruiting
- Krankenhaus Der Elisabethinen Linz Gmbh
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- age >17
- pulmonary arterial hypertension WHO group I who are going to start a therapy with prostanoid
- written informed consent
- Prostanoid naive
- no change of the pulmonary arterial hypertension therapy within 3 weeks of inclusion into the study
Exclusion Criteria:
- pregnancy and lactation period
- Women of childbearing potential who do not use an effective and secure method for birth control
- severe chronic kidney insufficiency (glomerular filtration rate <30), which will remain for more than 3 months
- liver insufficiency Child C
- life expectancy shorter than the course of the study (for example because of a malignant disease)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
3D echocardiography
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
right ventricular ejection fracture
Time Frame: month 12 (+/- 7 days)
|
right-sided heart catheterization
|
month 12 (+/- 7 days)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
right atrial pressure
Time Frame: 12 month (+/- 7 days)
|
right-sided heart catheterization
|
12 month (+/- 7 days)
|
|
cardiac index (CI)/cardiac output (CO)
Time Frame: 12 months (+/- 7 Days)
|
right-sided heart catheterization
|
12 months (+/- 7 Days)
|
|
pulmonary vascular resistance
Time Frame: 12 months (+/- 7 days)
|
right-sided heart catheterization
|
12 months (+/- 7 days)
|
|
mean pulmonary capillary wedge pressure
Time Frame: 12 month (+/-7 days)
|
right-sided heart catheterization
|
12 month (+/-7 days)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Protocol PARIS3D
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.